Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
Read MoreAs digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.
Read MoreAs digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.
Read MorePresident and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes
Read MoreThis new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
Read MoreBiopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships
Read MoreThe biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
Read MoreGB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world.
Read MoreDr. Andrea Small-Howard will be speaking as a part of the live Pain, Migraine & Addiction Panel on April 29 at 11:50 a.m. EDT, and she will be presenting the company during the 20-minute SPOTLIGHT SHOWCASE.
Read MoreGBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market. This is the intersection of hard science, plant-based medicine, and solid business practices.
Read MoreGB Sciences and their Spanish research partners at the Universidad de Sevilla (USE) have created terpene-containing nanoparticles. These first of their kind nanoparticles are central to GB Sciences' time-released pain formulations that are currently in animal trials at the NRC Canada, in preparation for an IND-filing for a US FDA-registered clinical trial.
Read MoreIf successful, data from this preclinical study would be used as part of the support for an Independent New Drug (IND)-filing with the US Food and Drug Administration (FDA) for the use of GBS' Cannabinoid Containing Complex Mixtures (CCCM™) to treat the potentially-fatal Cytokine Release Syndrome associated with COVID-19 and other dangerous hyperinflammatory conditions.
Read More